Table 1.
Baseline demographic and clinical characteristics for the 2009 first-time MI population
| Patients with PCI (N=3576, 50%) |
Patients without PCI (N=3528, 50%) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All patients n=3576 |
Clopidogrel n=3087 |
Ticagrelor n=0 |
Prasugrel n=13 |
No DAPT n=476 |
All patients n=3528 |
Clopidogrel n=1712 |
Ticagrelor n=0 |
Prasugrel n=1 |
No DAPT n=1815 |
|
| Age (median (IQR)) | 64 (55–73) | 64 (55–73) | – | 57 (50–64) | 68 (59–75) | 74 (64–83) | 74 (64–83) | – | 49 (49–49) | 74 (63–84) |
| Males | 2643 (73.9%) | 2289 (74.1%) | 0 (%) | 8 (61.5%) | 346 (72.7%) | 1951 (55.3%) | 956 (55.8%) | 0 (%) | 0 (0.0%) | 995 (54.8%) |
| Type of hospital (at index MI event) | ||||||||||
| Local hospital | 946 (26.5%) | 805 (26.1%) | 0 (%) | 5 (38.5%) | 136 (28.6%) | 1440 (40.8%) | 659 (38.5%) | 0 (%) | <5 | 780 (43.0%) |
| Main regional hospital | 1149 (32.1%) | 1005 (32.6%) | 0 (%) | 5 (38.5%) | 139 (29.2%) | 1150 (32.6%) | 616 (36.0%) | 0 (%) | 0 (0.0%) | 534 (29.4%) |
| Tertiary cardiac hospital | 1481 (41.4%) | 1277 (41.4%) | 0 (%) | <5 | 201 (42.2%) | 938 (26.6%) | 437 (25.5%) | 0 (%) | 0 (0.0%) | 501 (27.6%) |
| Procedures (at index event) | ||||||||||
| CABG | 80 (2.2%) | 47 (1.5%) | 0 (%) | 0 (0.0%) | 33 (6.9%) | 412 (11.7%) | 197 (11.5%) | 0 (%) | 0 (0.0%) | 215 (11.8%) |
| Angiography | 3535 (98.9%) | 3055 (99.0%) | 0 (%) | 13 (100.0%) | 467 (98.1%) | 1761 (49.9%) | 932 (54.4%) | 0 (%) | <5 | 828 (45.6%) |
| Previous diagnoses | ||||||||||
| Heart failure | 100 (2.8%) | 71 (2.3%) | 0 (%) | 0 (0.0%) | 29 (6.1%) | 343 (9.7%) | 148 (8.6%) | 0 (%) | 0 (0.0%) | 195 (10.7%) |
| Ischaemic heart disease | 256 (7.2%) | 181 (5.9%) | 0 (%) | <5 | 74 (15.5%) | 488 (13.8%) | 199 (11.6%) | 0 (%) | 0 (0.0%) | 289 (15.9%) |
| Unstable angina | 55 (1.5%) | 43 (1.4%) | 0 (%) | 0 (0.0%) | 12 (2.5%) | 107 (3.0%) | 50 (2.9%) | 0 (%) | 0 (0.0%) | 57 (3.1%) |
| Peripheral arterial disease | 94 (2.6%) | 67 (2.2%) | 0 (%) | 0 (0.0%) | 27 (5.7%) | 246 (7.0%) | 118 (6.9%) | 0 (%) | 0 (0.0%) | 128 (7.1%) |
| Stroke total | 132 (3.7%) | 98 (3.2%) | 0 (%) | <5 | 33 (6.9%) | 338 (9.6%) | 160 (9.3%) | 0 (%) | 0 (0.0%) | 178 (9.8%) |
| Non-ischaemic stroke | <5 | <5 | 0 (%) | 0 (0.0%) | <5 | 19 (0.5%) | 7 (0.4%) | 0 (%) | 0 (0.0%) | 12 (0.7%) |
| Ischaemic stroke | 130 (3.6%) | 96 (3.1%) | 0 (%) | <5 | 33 (6.9%) | 328 (9.3%) | 155 (9.1%) | 0 (%) | 0 (0.0%) | 173 (9.5%) |
| Atrial fibrillation | 125 (3.5%) | 93 (3.0%) | 0 (%) | 0 (0.0%) | 32 (6.7%) | 375 (10.6%) | 132 (7.7%) | 0 (%) | 0 (0.0%) | 243 (13.4%) |
| Chronic renal dysfunction | 16 (0.4%) | 11 (0.4%) | 0 (%) | 0 (0.0%) | 5 (1.1%) | 43 (1.2%) | 18 (1.1%) | 0 (%) | 0 (0.0%) | 25 (1.4%) |
| Diabetes mellitus | 396 (11.1%) | 327 (10.6%) | 0 (%) | <5 | 68 (14.3%) | 625 (17.7%) | 304 (17.8%) | 0 (%) | 0 (0.0%) | 321 (17.7%) |
| Major bleeding | 93 (2.6%) | 75 (2.4%) | 0 (%) | 0 (0.0%) | 18 (3.8%) | 189 (5.4%) | 67 (3.9%) | 0 (%) | 0 (0.0%) | 122 (6.7%) |
| Liver disease | <5 | <5 | 0 (%) | 0 (0.0%) | 0 (0.0%) | 5 (0.1%) | <5 | 0 (%) | 0 (0.0%) | <5 |
| Coagulation disorders | 9 (0.3%) | 8 (0.3%) | 0 (%) | 0 (0.0%) | <5 | 21 (0.6%) | <5 | 0 (%) | 0 (0.0%) | 17 (0.9%) |
| Cancer | 193 (5.4%) | 158 (5.1%) | 0 (%) | <5 | 34 (7.1%) | 333 (9.4%) | 146 (8.5%) | 0 (%) | 0 (0.0%) | 187 (10.3%) |
| Drug use at discharge | ||||||||||
| Total number of drugs (median (IQR)) | 3 (1–6) | 3 (1–6) | – | 4 (0–8) | 4 (2–8) | 6 (3–10) | 6 (3–10) | – | 13 (13–13) | 7 (3–11) |
| ACE inhbitors and ARB | 1948 (54.5%) | 1678 (54.4%) | 0 (%) | 7 (53.8%) | 263 (55.3%) | 1984 (56.2%) | 992 (57.9%) | 0 (%) | 0 (0.0%) | 992 (54.7%) |
| Acetyl salicylic acid | 3379 (94.5%) | 3087 (100.0%) | 0 (%) | 13 (100.0%) | 279 (58.6%) | 2962 (84.0%) | 1712 (100.0%) | 0 (%) | <5 | 1249 (68.8%) |
| β-blocker | 3170 (88.6%) | 2760 (89.4%) | 0 (%) | 12 (92.3%) | 398 (83.6%) | 2537 (71.9%) | 1389 (81.1%) | 0 (%) | 0 (0.0%) | 1148 (63.3%) |
| Calcium-channel blocker | 749 (20.9%) | 621 (20.1%) | 0 (%) | <5 | 127 (26.7%) | 1027 (29.1%) | 474 (27.7%) | 0 (%) | <5 | 552 (30.4%) |
| Oral antidiabetics and insulin | 369 (10.3%) | 308 (10.0%) | 0 (%) | <5 | 60 (12.6%) | 562 (15.9%) | 277 (16.2%) | 0 (%) | 0 (0.0%) | 285 (15.7%) |
| Proton pump inhibitors | 916 (25.6%) | 772 (25.0%) | 0 (%) | <5 | 140 (29.4%) | 1302 (36.9%) | 579 (33.8%) | 0 (%) | <5 | 722 (39.8%) |
| Statins | 3379 (94.5%) | 2954 (95.7%) | 0 (%) | 12 (92.3%) | 413 (86.8%) | 2523 (71.5%) | 1427 (83.4%) | 0 (%) | <5 | 1095 (60.3%) |
| Anticoagulant | 224 (6.3%) | 162 (5.2%) | 0 (%) | <5 | 61 (12.8%) | 415 (11.8%) | 113 (6.6%) | 0 (%) | 0 (0.0%) | 302 (16.6%) |
| NSAIDs | 613 (17.1%) | 531 (17.2%) | 0 (%) | 5 (38.5%) | 77 (16.2%) | 606 (17.2%) | 280 (16.4%) | 0 (%) | 0 (0.0%) | 326 (18.0%) |
| Time until P2Y12 antagonist prescription claimed | ||||||||||
| Prior to MI | 122 (3.4%) | 103 (3.3%) | 0 (%) | <5 | 18 (3.8%) | 167 (4.7%) | 125 (7.3%) | 0 (%) | 0 (0.0%) | 42 (2.3%) |
| 1–7 days | 3033 (84.8%) | 2825 (91.5%) | 0 (%) | 11 (84.6%) | 197 (41.4%) | 1600 (45.4%) | 1438 (84.0%) | 0 (%) | <5 | 161 (8.9%) |
| 8–14 days | 52 (1.5%) | 48 (1.6%) | 0 (%) | 0 (0.0%) | <5 | 69 (2.0%) | 65 (3.8%) | 0 (%) | 0 (0.0%) | <5 |
| 15–30 days | 120 (3.4%) | 111 (3.6%) | 0 (%) | <5 | 8 (1.7%) | 91 (2.6%) | 84 (4.9%) | 0 (%) | 0 (0.0%) | 7 (0.4%) |
| No prescription | 249 (7.0%) | 0 (0.0%) | 0 (%) | 0 (0.0%) | 249 (52.3%) | 1601 (45.4%) | 0 (0.0%) | 0 (%) | 0 (0.0%) | 1601 (88.2%) |
Numbers in parentheses are percentages of total number of patients in the group; local hospital, hospital without catheterisation laboratory; main regional hospital, hospital with catheterisation laboratory; tertiary cardiac hospital, university hospital with catheterisation laboratory.
ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; DAPT, dual antiplatelet therapy; MI, myocardial infarction; NSAIDs, non-steroidal anti-inflammatory drugs; PCI, percutaneous coronary intervention.